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Background. In utero transmission of HIV-1 occurs on average in only 3%–15% of HIV-1-exposed neonates born to mothers
not on antiretroviral drug therapy. Thus, despite potential exposure, the majority of infants remain uninfected. Weak HIV-1-
specific T-cell responses have been detected in children exposed to HIV-1, and potentially contribute to protection against
infection. We, and others, have recently shown that the removal of CD4
+CD25
+ T-regulatory (Treg) cells can reveal strong HIV-1
specific T-cell responses in some HIV-1 infected adults. Here, we hypothesized that Treg cells could suppress HIV-1-specific
immune responses in young children. Methodology/Principal Findings. We studied two cohorts of children. The first group
included HIV-1-exposed-uninfected (EU) as well as unexposed (UNEX) neonates. The second group comprised HIV-1-infected
and HIV-1-EU children. We quantified the frequency of Treg cells, T-cell activation, and cell-mediated immune responses. We
detected high levels of CD4
+CD25
+CD127
2 Treg cells and low levels of CD4
+ and CD8
+ T cell activation in the cord blood of the
EU neonates. We observed HIV-1-specific T cell immune responses in all of the children exposed to the virus. These T-cell
responses were not seen in the cord blood of control HIV-1 unexposed neonates. Moreover, the depletion of CD4
+CD25
+ Treg
cells from the cord blood of EU newborns strikingly augmented both CD4
+ and CD8
+ HIV-1-specific immune responses.
Conclusions/Significance. This study provides new evidence that EU infants can mount strong HIV-1-specific T cell
responses, and that in utero CD4
+CD25
+ T-regulatory cells may be contributing to the lack of vertical transmission by reducing
T cell activation.
Citation: Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, et al (2006) Strong HIV-1-Specific T Cell Responses in HIV-1-Exposed Uninfected Infants
and Neonates Revealed after Regulatory T Cell Removal. PLoS ONE 1(1): e102. doi:10.1371/journal.pone.0000102
INTRODUCTION
Vertical transmission of HIV-1 can occur in utero, during labor, or
after delivery. In the absence of antiretroviral prophylaxis and in
a non-breastfeeding population, in utero transmission occurs on
average in only 3-15% of HIV-1-exposed infants [1]. Multiple
factors increase the risk of in utero vertical transmission, and include
low maternal CD4
+ lymphocyte count or high viral load, preterm
delivery, and chorioamnionitis [2–5]. Interestingly, despite
potential exposure to HIV-1, including peripartum and through
breastfeeding, most infants born to untreated mothers remain
uninfected. Several potential genetic, virologic, and immunologic
explanations have been provided to explain the lack of trans-
mission (reviewed in [6]), but none have been clearly defined as
actively contributing to lower rates of HIV-1 infection in the
neonate.
Multiple lines of evidence demonstrate that HIV-1-specific
CD8
+ T cell responses contain and suppress viremia. Such
responses are correlated with early control of viral replication
during primary infection [7–8], and their loss has been linked to
rapid disease progression [9]. In the rhesus macaque-simian
immunodeficiency virus (SIV) model, the depletion of CD8
+ T
cells leads to increased viral replication [10], which is reversed
with the with the reappearance of SIV-specific CD8
+ T cells [11].
High levels of anti-HIV-1 CD8
+ T cell responses have been
associated with lack of disease in long-term non-progressing
patients [9,12–15]. Finally, in both acute and chronic HIV-1
infections, the emergence of CTL escape mutants highlights the
role of immunological pressure on viral replication [7,16–17].
HIV-1-specific CD8
+ T cell-mediated cytolysis is detectable in
infected children [18–27]; however, these responses are less
frequent and weaker in magnitude than in adults and do not
always appear before six months of age [28]. Age plays a major
role in determining the quality of the HIV-1-specific cellular
immune responses. In HIV-1-infected children younger than four
years of age, CD8
+ T cells secreting IFN-c in response to HIV-1
peptides are low in frequency and lack breadth [27]. Researchers
have attributed this to the lack of effective HIV-1-specific CD4
+ T-
helper responses (abnormal skewing of CD4 differentiation to
a higher Th2:Th1 ratio) and deficiencies in T-cell priming and
effector functions [19,27–29].
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children who have been exposed to the virus yet remained
uninfected. CD8
+ immune responses to HIV-1 Env, Gag, and Nef
proteins have been shown in the peripheral blood of these infants
early after birth [19]. In addition, HIV-1-specific CD8
+ IFN-c
responses have been detected in the peripheral blood of 25% of
exposed uninfected infants between 15 to 50 months of age [23] as
well as in an uninfected infant using virus-specific stimulation [20].
Recently, it was shown that at one month of age, 58% of infants
infected in utero and 29% of those infected peripartum exhibited
HIV-1-specific cellular immune responses by ELISPOT [28].
The ability of young infants to mount T cell responses has been
supported by some recent studies that suggest that neonatal mice
are able to generate robust CD8
+ T cell responses [30]. The
responding T cells were able to produce a similar range of
cytokines and avidities as that of adults. Following congenital
infection, newborns develop a mature CD8
+ T cell response to
human cytomegalovirus (HCMV) [31–32]. This response is similar
to that detected in adults and the HCMV-specific CD8
+ T cells
express a mature memory phenotype, have antiviral effector
functions, produce IFN-c, and have perforin dependent cytolytic
activity (reviewed in [33]). In a study of neonatal cord-blood T
cells congenitally infected with Trypanosoma cruzi, the protozoan
agent of Chagas disease, it was demonstrated that fetal cells have
the ability to generate potent and ‘‘adult-like’’ CD8
+ T cell
responses [34].
The role of CD4 T cell help in inducing functional CD8 T cell
responses needs further investigation; however, CD4
+ T cell
responses have been enumerated in early life. Young infants are
able to mount mature CD4 T cell responses to Bordetella pertussis
vaccine [35], to herpes simplex virus infection [36], and to in utero
exposure to helminth antigens [37]. In HCMV infection, young
infants develop mature CD8 T cell responses in the context of low
CD4 T cell immune responses whereas in HIV-1 infection CD4 T
cell help is integral in controlling HIV-1 infection.
Following the assumption that the young infant can in certain
cases mount robust immune responses, we aimed to evaluate the
strength of HIV-1-specific immune responses around the time of
exposure to the virus and the potential impact of these responses
on maternal-infant transmission. We hypothesized that these
immune responses may be unmasked upon the removal of
CD4
+CD25
+ Tregulatory (Treg) cells. We, and others, have
shown that this phenomenon occurs in HIV-1 infected adults [38].
We measured HIV-1-specific immune responses and determined
the frequency and the suppressive activity of Tregs in the cord
blood of HIV-1-exposed uninfected (EU) neonates, as well as in
the peripheral blood of HIV-1-infected and EU infants and young
children. We detected HIV-1-specific T cell immune responses in
all of the children exposed to the virus, including vigorous
responses in EU children two years after birth. In addition,
depletion of CD4
+CD25
+ Treg cells from the cord blood of EU
neonates augmented both CD4 and CD8 HIV-1-specific immune
responses.
MATERIALS AND METHODS
Patient samples and viral load measurements
HIV-1-infected and control uninfected mothers and their infants
were followed and treated at the Federal University of Sa ˜o Paulo
hospital (Sa ˜o Paulo, Brazil). Perinatally HIV-1-infected and
exposed uninfected pediatric subjects were followed and treated
at the Jacobi Medical Center (Bronx, New York). EDTA-treated
whole cord blood and peripheral blood samples (2–5 mL) were
collected at birth or during scheduled monthly visits after
obtaining informed consent based on local Institutional Review
Board-approved protocols. An infant was categorized as un-
infected if the infant had 2 negative HIV-1 DNA PCR assay
results at separate visits 1 month after birth, the second one after 4
months of age. Infants not meeting these criteria were classified as
having an indeterminate infection status and were excluded from
this study. Positive results of HIV-1 DNA PCR assay were
confirmed by HIV-1 RNA PCR assay or HIV culture. Cord blood
mononuclear cells (CBMCs) and PBMCs were isolated by Ficoll-
Paque PLUS density gradient centrifugation (Amersham Pharma-
cia Biotech, Uppsala, Sweden) and cryopreserved. Selection bias
was avoided by blinding samples for all performed assays. Patient
samples were selected on having a cell viability of .80%. Those
samples not meeting this criterion were not assayed. All assayed
patient samples are represented. Plasma HIV-1 RNA was
measured with Amplicor HIV-1 Monitor (version 1.5) with a lower
limit of quantification at 400 copies of RNA/mL (Roche
Diagnostic Systems, Branchburg, NJ). Absolute levels of CD4
+
T-cells were determined by flow cytometry with the BD MultiTest
CD3/CD4/CD8/CD45 Reagent Kit and analyzed on a FACS-
Calibur flow cytometer (BD Biosciences, San Jose, CA).
Immunophenotyping
Cryopreserved CBMCs and PBMCs were thawed, washed, and
incubated overnight at 37uCi n5 %C O 2. CBMCs and PBMCs
(2610
5) were resuspended in PBS (Media Tech, Herndon, VA)
and 1% BSA (Sigma, St Louis, MO). CBMCs and PBMCs were
stained for activation markers with each of the following mono-
clonal antibodies (BD Biosciences): CD3-PerCP, CD4-allophyco-
cyanin (APC), HLA-DR-FITC, and QuantiBRITE CD38-PE.
CBMCs and PBMCs were also stained for Treg phenotypic
markers with each of the following monoclonal antibodies (BD
Biosciences): CD3-PE-Cy7, CD4-allophycocyanin-Cy7 (APC-
Cy7), CD25-APC, CD127-PE (Beckman Coulter Biosciences),
and CD45RA-PE-Cy5. Cells were incubated for 30 min at 4uC,
washed, and analyzed on a FACSCalibur flow cytometer,
according to the manufacturer’s specifications. Calibrated Quanti-
BRITE fluorescent beads were used to construct a standard curve
for quantification of CD38. FlowJo software (TreeStar, Ashland,
OR) was employed to convert the measured sample mean
fluorescence intensity to antibodies bound per cell (ABC).
Depletion of CD4
+CD25
+ Treg Cells
CD4
+CD25
+ Treg cells were purified with MACS CD25
MicroBeads (Miltenyi Biotec, Auburn, CA). Briefly, CBMCs and
PBMCs were washed twice in PBS containing 0.5% BSA and
2 mM EDTA, resuspended in PBS containing 0.5% BSA, 2 mM
EDTA and 20 mL of MACS CD25 MicroBeads per 10
7 total
CBMC or PBMC, and incubated for 15 minutes at 6 to 12uC.
CBMCs and PBMCs were washed twice in PBS containing 0.5%
BSA and 2 mM EDTA and applied to a magnetic column on
a MiniMACS separation unit (Miltenyi Biotec). CD25-containing
and CD25-depleted T-cell fractions were collected. The CD25-
containing cell fraction contained 90% CD4
+ T cells.
Cytokine flow cytometry
Cryopreserved CBMCs and PBMCs were thawed, washed in
RPMI-1640 medium (Media Tech) supplemented with 15% FBS
(Gemini, Woodland, CA) and incubated overnight at 37uCi n5 %
CO2. HIV-1 specific responses were determined by using pools of
overlapping HIV-1 clade B 15-mer peptides spanning the Gag
(123 peptides, BD Biosciences) and Nef regions (49 peptides; AIDS
Research and Reference Reagent Program, NIAID, NIH).
Tregs in HIV-Exposed Infants
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a positive control antigen. Briefly, 2610
5 CBMCs and PBMCs
were resuspended in RPMI-15% FBS and incubated with each
peptide pool (5 mg/ml for each peptide) at 37uCi n5 %C O 2 for
18 h. Brefeldin A (10 mg/mL; Sigma) was added, and the cells
were incubated for an additional 5 h at 37uCi n5 %C O 2. Cells
were then washed in PBS with 0.02% EDTA and 1% BSA and
transferred to a 96-well V-bottom plate, and permeabilized with
a 0.1% Saponin solution, and surface stained with the following
monoclonal antibodies (BD Biosciences): CD3-PerCP, CD4-APC-
Cy7, IL-2-PE, TNF-a-APC, and IFN-c-PE-Cy7 for 30 min at
room temperature. Finally, cells were washed, fixed with 1%
paraformaldehyde, and analyzed on a FACSCanto or LSRII flow
cytometer (BD Biosciences). The data were analyzed with FlowJo
software. Samples were gated on CD3
+CD4
+ or CD3
+CD4
2
(CD8
+) lymphocytes and analyzed for IL-2, TNF-a, and IFN-c
expression (Figure 1). Results were expressed as the percentage of
CD3
+CD4
+ or CD3
+CD4
2 (CD8
+) expressing IL-2, TNF-a and
IFN-c. HIV-specific responses were considered positive when the
response was 2 S.D. above the mean background for all the
peptide pools, the cutoff value was 0.13% IFN-c-producing CD3
+
T cells.
Microchimerism Assay
We investigated the presence of maternal cells in each child’s
circulation using a multiplex PCR for four Short Tandem Repeats
Loci (vWA, D8S1179, TPOX, FGA) and a sex-identification
marker (Amelogenin locus) discriminated by fragment analysis.
The sensitivity of the method includes detection of 1% of mixture
of DNAs from different individuals (data not shown). Results
showed distinct maternal and child profiles as we were unable to
find evidence of cell microchimerism in the children samples.
Statistical analysis
Statistical analyses were performed with GraphPad Prism (release
4.0, GraphPad Software, San Diego, CA). Comparisons of
immune parameters were performed using nonparametric meth-
ods, the Mann-Whitney test for independent samples and
Wilcoxon matched pairs test for paired samples. Differences were
considered significant if p,0.05.
RESULTS
Subjects
Our objective was to measure HIV-1-specific T cell immune
responses at the time of delivery and within the first year of life.
Furthermore, we wanted to establish whether these responses were
sustained and whether Treg cells suppressed virus specific
responses in an age dependent manner. We evaluated neonatal
cord blood samples from a cohort of children in Sao Paulo, Brazil.
We performed a retrospective study using cryopreserved cord
blood samples from six HIV-1-EU (CB-EU) and four non-exposed
neonates (CB-UNEX). All mothers received prenatal care and all
HIV-1-infected mothers were placed on triple antiretroviral
therapy during pregnancy (Table 1). Five of the 6 mothers had
plasma HIV-1 RNA levels below 400 copies/ml in the last month
of pregnancy; the sixth mother had a viral load of 3.64 log copies/
mL.
In addition, we examined peripheral blood samples of young
infants within the first year of life as well as a subsequent time-
point. These children were followed at the Jacobi Medical Center
in the Bronx, NY. We analyzed cryopreserved peripheral blood
mononuclear cells from five HIV-1-infected (PB-INF-7mo;
median age 7.4 months) and nine EU infants (PB-EU-7mo;
median age 6.5 months) as well as five HIV-1-infected (PB-INF-
25mo; median age 24.8 months) and seven EU young children
(PB-EU-20mo; median age 20 months; Table 2). All HIV-1
infected mothers treated at the Jacobi Medical Center received
prenatal care and were on triple antiretroviral therapy during
pregnancy. Maternal viral loads were not available for the Jacobi
cohort.
Higher levels of CD4
+CD25
+CD127
2 Treg cells in
neonatal cord blood
The current phenotypic definition of Treg cells is based primarily
on the expression of CD4 and CD25 as well as the selective
expression of the transcription factor Foxp3 [39–41]. At the time
of this study a human FoxP3 antibody for flow cytometry was not
available. However, recent research has demonstrated that CD127
expression is inversely correlated with FoxP3 expression and
suppressive function of human Treg cells [42–43]. CD127 is part
of the heterodimeric IL-7 receptor that plays an important role in
Figure 1. CD4
+ and CD8
+ T cell immune responses were measured by
cytokine flow cytometry. A) Gating strategy for the identification of
polyfunctional IFN-gamma/TNF-alpha CD8
+ T cell responses. B) Shown
are representative data for the unstimulated and HIV-gag-specific
response from subject PB-INF-4 after an 18 h in vitro stimulation.
doi:10.1371/journal.pone.0000102.g001
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experiments show that the expression of CD127 is down-regulated
following T cell activation [44]. We therefore quantified the
frequency of Treg cells by utilizing a combination of the cell
surface molecules CD4, CD25 and CD127. Using flow cytometry,
we detected the highest level of CD4
+CD25
+CD127
2 Treg cells in
the cord blood of EU neonates (1.55%, Mann-Whitney test;
Table 2) as compared to unexposed neonates (0.62%; p=0.0947)
and HIV-1-infected (0.16%; p=0.0193) and EU infants (0.27%;
p=0.0062).
Decreased activation levels in HIV-1-exposed-
uninfected neonatal cord blood
T-cell activation in HIV-1-infected individuals was measured with
the markers HLA-DR and CD38 on CD4
+ and CD8
+ T cells. As
expected, CD4
+ and CD8
+ activation levels were highest in HIV-
1-infected infants (Mann-Whitney test, p=0.0732; Table 3). T-cell
activation levels as measured by the percentage of cells expressing
both HLA-DR and CD38 did not differ significantly in the EU or
unexposed neonatal cord blood samples (Mann-Whitney test,
p=0.9015 and p=0.8048, respectively).
HIV-1-specific immune responses in exposed-
uninfected neonates and infants
We measured HIV-1-specific as well superantigen-specific im-
mune responses in unexposed and EU neonatal cord blood, HIV-
1-EU infants and young children, as well as HIV-1-infected infants
and young children. As we were limited by cell number, we chose
the most immunogenic proteins Gag and Nef. We selected one
HIV structural (Gag) and one non-structural protein (Nef) for our
immunological assays. As this was a retrospective study, only two
exposed uninfected infants (PB-EU-2 and PB-EU-5) were followed
at both an early as well as a late time point. In total, 9 exposed
uninfected infants were analyzed at an early time point (7 months
of age) and 7 exposed uninfected infants at a later time point (20
months of age). The strength of the CD4
+ and CD8
+ T-cell
mediated immune response to HIV-1 Gag and Nef proteins was
measured by intracellular cytokine production using flow cyto-
metry. We utilized pools of 15-mer overlapping peptides to
measure production of IFN-c in both the cord blood and
peripheral blood mononuclear cells.
Significant IFN-c production by CD8
+ T cells in response to the
Gag and Nef peptide pools was detected in EU neonates, infants
and young children as well as infected infants and young children
(Figure 2A, 2B). Interestingly, both Gag and Nef specific CD8
+ T
cell IFN-c responses were sustained in the majority of exposed
uninfected children well into the second year of life, and the
strength of these responses was comparable to age-matched HIV-
1-infected young children. Also, the magnitude of IFN-c immune
responses in EU cord blood was higher than in the peripheral
blood. Substantial cytokine production to HIV-1 antigens was not
evident in unexposed control cord blood by either CD4
+ or CD8
+
T cells (data not shown and Fig. 2, respectively). All groups,
including unexposed neonates, elicited a strong CD8
+ T cell IFN-c
response to Staphylococcus enterotoxin B (SEB) (Figure 2C).
Polyfunctional Gag-specific CD8
+ T cell immune
responses in exposed-uninfected young children
The presence of cells secreting IL-2, IFN-c and TNF-a has been
associated with the lack of disease progression in human long term
non-progressors (LTNPs) [45]. HIV-1-specific CD8
+ T cells that
simultaneously produce both IFN-c/TNF-a upon stimulation have
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c/TNF-a cytokine secretion in the cord blood of EU neonates as
well as in HIV-1-infected young children (Figure 3A). IFN-c/IL-2-
secreting CD8
+ T cells have been shown to promote CD8
+ T cell
proliferation through the secretion of IL-2 even in the absence Ag-
specific helper CD4
+ T cells [47]. These polyfunctional IFN-c/IL-
2 CD8
+ T-cell immune responses were detected in the cord blood
of EU neonates and in the peripheral blood of EU as well as HIV-
1 infected infants and children (Figure 3B). IFN-c/IL-2 CD8
+
responses were significantly increased in the second year of life in
both HIV-1-EU and HIV-1-infected young children. (Wilcoxon
matched-pair test,p =0.0115 and p=0.0303, respectively)
(Figure 3B).
Augmented Gag CD8
+ IFN-c and CD4
+ IL-2 immune
responses in exposed-uninfected neonatal cord
blood upon the removal of Treg cells
We next wanted to determine the suppressive activity of Treg cells
in the cord blood of HIV-1-EU neonates and in the peripheral
Table 3. Patient T-regulatory phenotypes (median).
..................................................................................................................................................
Patient Group
T-reg Phenotype
(% CD4
+CD25
+CD127
2) P values
CD4 Activation (%
CD4
+HLA-DR
+CD38
+)
CD8 Activation (%
CD8
+HLA-DR
+CD38
+)
Unexposed Cord Blood 0.62 – 1.69 1.77
Exposed Uninfected Cord Blood 1.55 p=0.0947(vs. CB-Unexp) 2.07 1.34
Exposed Uninfected Peripheral Blood 0.27 p=0.0062 (vs. CB-EU) 2.18 3.09
HIV-Infected Peripheral Blood 0.16 p=0.0193 (vs. CB-EU) 3.39 4.30
doi:10.1371/journal.pone.0000102.t003
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Table 2. HIV-exposed uninfected infant (median age 6.5 months), follow-up HIV-exposed uninfected young children (median age
19.8 months), HIV-infected infant (median age 7.4 months), and two year follow-up young children (median age 24.8 months)
patient characteristics.
..................................................................................................................................................
Patient ID
Age at Sampling
(months)
Age at Follow-up Sampling
(months)
Viral Load
(log10 RNA copies/mL)
CD4 count
(cells/mL) Treatment History
2
PB-INF-1 6.9 –
1 .5.875 904 d4T, 3TC, Kaletra
PB-INF-2 13.4 – 4.769 1508 Naive
PB-INF-3 1.9 – 3.906 3106 d4T, 3TC, NFV
PB-INF-3 – 22.4 ,1.699 2325 3TC, Kaletra, ABC
PB-INF-4 7.4 – 5.318 2959 d4T, 3TC
PB-INF-4 – 29 4.255 853 d4T, 3TC, NFV
PB-INF-5 13.2 – 3.351 1758 Naive
PB-INF-6 – 24.8 ,1.699 2195 d4T, 3TC, Kaletra
PB-INF-7 – 26.8 1.740 1678 d4T, 3TC
PB-INF-8 – 20.8 2.776 3986 d4T, 3TC
PB-EU-1 6.5 – – – –
PB-EU-2 6.5 – – – –
PB-EU-2 – 12.3 – – –
PB-EU-3 9.2 – – – –
PB-EU-4 7.2 – – – –
PB-EU-5 1.4 – – – –
PB-EU-5 – 12.4 – – –
PB-EU-6 6.5 – – – –
PB-EU-7 1.1 – – – –
PB-EU-8 2.4 – – – –
PB-EU-9 0.57 – – – –
PB-EU-10 – 12.2 – – –
PB-EU-11 – 19.9 – – –
PB-EU-12 – 25.4 – – –
PB-EU-13 – 20.9 – – –
PB-EU-14 – 19.8 – – –
1–,Not applicable
23TC, lamivudine; ABC, zidovudine/lamivudine/abacavir; d4T, stavudine; NFV, nelfinavir
doi:10.1371/journal.pone.0000102.t002
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PLoS ONE | www.plosone.org 5 December 2006 | Issue 1 | e102blood of HIV-1-EU and infected infants and young children. Cells
were counted prior to the depletion and then the CD4
+CD25
+
Treg cells were depleted. The Treg depleted PBMCs were then
recounted and 2610
5 cells were assayed for immune responses.
The depletion of CD4
+CD25
+ T-cells significantly augmented
Gag-specific CD8
+ T cell responses from the cord blood of EU
neonates (Figure 4A), increasing by up to 3.37 fold (p=0.0152). In
Patient 30, the CD8
+ T-cell IFN-c response was particularly robust,
reaching 2.59% upon CD4
+CD25
+ T-cell depletion (Figure 4B).
We also measured CD4
+ T cell responses to HIV-1 peptides
in the presence and absence of Treg cells. Significant IL-2
(Mann-Whitney test, p=0.0158, Figure 5A) cytokine production
by CD4
+ T-cells in response to the Gag peptides were observed
in EU neonatal cord blood as compared to unexposed cord
blood. Moreover, upon the depletion of CD4
+CD25
+ Treg cells,
IL-2 responses to Gag were augmented significantly, increasing
by up to 2.87 fold (Wilcoxon matched-pair test, p=0.0411). In
one EU neonate (Patient 63), CD4
+ IL-2 production in response
to HIV-1 antigens in the whole cord blood mononuclear cell
population as well as in CD25-depleted cord blood cells was
striking, with responses reaching 5.77% after CD25-depletion
(Figure 5B). No significant cytokine production to HIV-1
antigens by CD4
+ or CD8
+ T cells was evident in unexposed
control whole or CD25-depleted cord blood. In general, both
CD8
+ IFN-c and CD4
+ IL-2 immune responses were lower in
the peripheral blood than in the cord blood. In the peripheral
blood, the depletion of CD4
+CD25
+ Treg cells did not
significantly impact the magnitude of the CD4
+ or CD8
+ T cell
immune response in either HIV-1-EU or HIV-1-infected infants
and children.
Figure 2. CD8
+ IFN-gamma T-cell immune responses to HIV-1 Gag (A)
and Nef (B) peptide pools as well as SEB (C) in the cord blood of
unexposed neonates (CB-UNEX; n=4), HIV-1-exposed uninfected
neonates (CB-EU; n=6), and in the peripheral blood of HIV-1-
exposed-uninfected infants (PB-EU 7 mo; n=9) and young children
(PB-EU 20 mo; n=7), and in HIV-1-infected infants (PB-INF 7 mo; n=5)
and young children (PB-INF 25 mo; n=5). Each group is represented by
a different symbol.
doi:10.1371/journal.pone.0000102.g002
Figure 3. Polyfunctional CD8
+ T cell immune responses to the HIV-1
Gag peptide pool were detected by cytokine flow cytometry. Responses
were measured in the cord blood of unexposed neonates (CB-UNEX;
n=4), HIV-1-exposed uninfected neonates (CB-EU; n=6), and in the
peripheral blood of HIV-1-exposed-uninfected infants (PB-EU 7 mo;
n=9) and young children (PB-EU 20 mo; n=7), and in HIV-1-infected
infants (PB-INF 7 mo; n=5) and young children (PB-INF 25 mo; n=5).
Each group is represented by a different symbol.
doi:10.1371/journal.pone.0000102.g003
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We detected strong, sustained HIV-1-specific immune responses in
EU newborns, infants and young children up to two years of age.
Unlike previous groups, we assessed HIV-1-specific immune
responses in neonates born to women receiving what is now
considered appropriate antenatal care for HIV-1-infected preg-
nant women, which includes antiretroviral therapy to achieve
undetectable viral loads before delivery and the provision of
elective caesarean section delivery independent of viral load levels
[4]. Earlier studies measuring responses from HIV-1 exposed
children were conducted prior to the widespread use of HAART
in pregnant women as a means to prevent mother-to-child
transmission [19–20,22–23]. Therefore, it is likely that such
children were exposed to high levels of maternal viremia. Our data
supports the notion that in utero exposure to HIV-1 or its viral
products induces HIV-1-specific cell-mediated immune responses
even in the setting of low maternal viral loads and does so within
a milieu of a low level of immune activation. Moreover, these
responses can persist at least well into the second year of life.
The magnitude of these HIV-1-specific memory T cell
responses in the absence of productive infection is surprising. It
is possible the children were exposed to high quantities of non-
infectious HIV-1 particles in utero, or alternatively infected
maternal lymphocytes or activated antigen presenting cells may
have microtransfused across the placenta, stimulating the fetal
immune system. However, we did not detect any maternally-
derived mononuclear cells in the neonatal cord blood samples.
Figure 4. Augmented CD8
+ HIV-1 immune responses to Gag peptide pools in exposed uninfected neonatal cord blood upon the removal of
CD4
+CD25
+ Treg cells. A) IFN-gamma production by undepleted whole cord blood and peripheral blood mononuclear cells (MNCs) derived CD8
+ T-
cells (open white symbols) and CD25-depleted MNCs derived CD8
+ T-cells (closed black symbols) is depicted. B) Flow cytometry plots from an
exposed uninfected neonate (Patient 30) representing HIV-1-Gag-induced IFN- gamma production in non-CD25-depleted CBMC derived CD8
+ T-cells
and CD25-depleted CBMC derived CD8
+ T-cells.
doi:10.1371/journal.pone.0000102.g004
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PLoS ONE | www.plosone.org 7 December 2006 | Issue 1 | e102Although the sensitivity of this method is approximately 1%, we
cannot preclude the possibility of the presence of maternal cells in
compartments other than the blood. Although highly unlikely
[48], we also cannot discard the hypothesis that the fetus of an
HIV-1-positive mother may become transiently infected with
HIV-1 and effectively clears the virus prior to birth. Alternatively,
we hypothesize that the prolonged low level of in utero antigen
exposure during gestation may enable the differentiation of
memory cells without a transition through a full effector phase.
Perhaps, low levels of antigen at the peak of the response trigger
a nominal level of activation allowing for proliferation without the
induction of full effector functions, which in turn favor the
development of precursors of long-lived memory T-cells.
HIV-1 infection is associated with CD4
+ T cell loss and
progressive immune dysfunction, leading to impaired HIV-1
responses early after infection. It has been hypothesized that the
basis for the early decrease in responses to HIV-1 relates to the
activity of Treg cells. One theory is that Treg cells influence HIV-1
infection by selectively inducing antigen specific suppression at an
early stage of infection, which in turn inhibit the adaptive T cell
response against the virus and perhaps self antigens and/or other
pathogens. Such suppression of HIV-1 specific T cell responses by
Treg cells has been reported in chronically HIV-1-infected adults
[38]. Alternatively, it has been proposed that Tregs may help
combat HIV-1 disease via suppression of CD4
+ T cell activation.
Oswald-Richter et al. showed that Treg cells are depleted at later
Figure 5. Augmented CD4
+ HIV-1 immune responses to Gag peptide pools in exposed uninfected neonatal cord blood upon the removal of
CD4
+CD25
+ Treg cells. A) IL-2 production by undepleted whole cord blood and peripheral blood mononuclear cells (MNCs) derived CD4
+ T-cells
(open white symbols) and CD25-depleted MNCs derived CD4
+ T-cells (closed black symbols) is depicted. B) Flow cytometry plots from an exposed
uninfected neonate (Patient 63) representing HIV-1 Gag induced IL-2 production in undepleted whole CBMC derived CD4
+ T-cells and CD25-depleted
CBMC derived CD4
+ T-cells.
doi:10.1371/journal.pone.0000102.g005
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PLoS ONE | www.plosone.org 8 December 2006 | Issue 1 | e102stages of HIV infection, which correlated with higher activated T
cells, and thus proposed that Treg cells could help reduce viral
loads by suppressing T cell activation [49]. This may effectively
lower the rate of HIV-1 replication by decreasing the pool of
available activated CD4
+ target cells [49–50]. In support, it has
been shown that healthy HIV-1-infected individuals have high
Treg frequencies [51]. Moreover, patients with Tregs exhibiting
strong ex-vivo T cell suppression have significantly lower levels of
plasma viremia and higher CD4
+ to CD8
+ T cell ratios than
patients without Treg cell activity [50].
Treg cells have been shown to have an age-dependent loss of
suppressive activity, where Treg cell levels are highest early in
gestational life and decrease with age [52]. Increased numbers of
fetal circulating Treg cells have been shown during early
pregnancy, peaking during the second trimester and then declining
postpartum [53]. In the cord blood of EU neonates, we observed
the highest levels of Treg cells and the lowest levels of T-cell
activation. Moreover, CBMCs exhibited full functional capacity
including polyfunctional IFN-c/TNF-a and IFN-c/IL-2 CD8
+
immune responses (Figure 3). Similar responses were not detected
in infant PBMCs and only emerged in the second year of life. We
posit that, in utero, Treg cells have a significant role in decreasing
activation levels, and in an environment of low activation,
polyfunctional HIV-1-specific immune responses, although lower
due to Treg activity, are sufficient to subvert vertical transmission.
After the neonatal period, in which Treg cells naturally decline,
the residual Treg cells in the EU infant may play a minimal role in
reducing activation levels and in suppressing immune responses.
Only with time, as the infant’s immune system matures, do
polyfunctional immune responses reemerge. Alternatively, it can
be hypothesized that Treg cell suppression of HIV-1-specific T
cells, rather than the presence of such responses, may prevent
immune activation and susceptibility to HIV transmission.
We measured significantly lower HIV-1-specific immune
responses in the peripheral blood than in the neonatal cord blood.
This may be a reflection of the fact that these samples are taken
later after HIV-1 exposure, wherein the frequency of circulating
effector memory cells has naturally waned. It can be further
conjectured that antigen presentation by activated and mature
maternal cells microtransfused through the placenta may contrib-
ute to the activation and augmentation of immune responses in
utero. Whereas postpartum, within the first year of life, antigen
presentation by the infant’s immature immune system is incapable
of inducing strong polyfunctional immune responses.
Overall, there are a limited number of neonatal immune
response studies in human newborns and infants, yet it is believed
that qualitative and quantitative differences when compared to
adult immune responses exist. The dogma in neonatal immunol-
ogy has been that newborns have an incompetent immune system,
developing only weak or even tolerogenic responses (reviewed in
[33]). Multiple lines of evidence, including our own, suggest that
this notion needs to be reconsidered. Mature responses to certain
vaccines and infectious pathogens have been observed during the
postnatal period and even during fetal life (reviewed in [33]). It is
evident that a diverse array of cellular immune responses can be
developed in early life, and these cells may be able to combat and
effectively clear pathogens such as HIV-1. These responses
however may be masked or hidden by the presence of antigen-
specific suppressor cells such as Treg cells or other as yet
unidentified cell populations.
In summary, our data reveals the presence of strong HIV-1-
specific T-cell responses in the cord blood and in the peripheral
blood of exposed-uninfected neonates and infants, respectively.
The magnitude of the immune response is highest in the cord
blood and lower in the peripheral blood. What role these cells may
play in protection from and/or clearance of vertically transmitted
HIV-1 infection is still not known. In the cord blood, CD4
+CD25
+
Treg cells significantly reduce activation levels and may provide
a mechanism for deterring vertical transmission. Characterization
of these HIV-1-specific T-cell responses will have important
implications for understanding maternal and fetal immunity
against HIV-1 during pregnancy and labor and neonatal vaccine
development.
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